In a report issued on July 13, Steve Beuchaw from Morgan Stanley maintained a Hold rating on Align Tech (NASDAQ: ALGN), with a price target of $315. The company’s shares closed on Friday at $363.45, close to its 52-week high of $371.55.
Beuchaw has an average return of 72.2% when recommending Align Tech.
According to TipRanks.com, Beuchaw is ranked #900 out of 4843 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Align Tech with a $344.60 average price target, which is a -5.2% downside from current levels. In a report issued on July 2, Stephens also maintained a Hold rating on the stock with a $265 price target.
.
See today’s analyst top recommended stocks >>
Based on Align Tech’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $95.87 million. In comparison, last year the company had a net profit of $69.18 million.
Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2018, Raymond Larkin, a Director at ALGN sold 15,000 shares for a total of $3,966,750.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Align Technology, Inc. engages in the manufacture, design, and marketing of global medical devices. It operates through the Clear Aligner, and Scanner and Services segments. The Clear Aligner segment consists of invisalign full, teen and assist products, and vivera retainers along with training and ancillary products for treating malocclusion.
